Cynthia Anneski, MD
Infectious Disease · Mesa, AZNPI 1326001892
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $802 of the $1,037 with a category attached, or 77.4%. 8 manufacturers reported payments, led by Astellas Pharma US Inc at 34.7% of the total. Reporting peaked in 2019 at $792 and has fallen 97.3% since, to $22 in 2025.
Across 52 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$360
- AbbVie$281
- Merck$230
- Paratek Pharmaceuticals, Inc.$55
- Tetraphase Pharmaceuticals, Inc.$39
- Boston Scientific$35
- plus $36 from 2 others
What the payments were for
- Food & beverage$80277%
- Education$23523%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 12 | $360 |
| AbbVie(2 entities) | 17 | $281 |
| Merck | 13 | $230 |
| Paratek Pharmaceuticals, Inc. | 4 | $55 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $39 |
| Boston Scientific | 2 | $35 |
| Leadiant Biosciences, Inc. | 1 | $20 |
| Abbott | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZERBAXA$100
How this compares
$1,037 in reported general payments places this provider in the 75th percentile of 146 infectious disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 111 | $27,824 |
| ErtapenemErtapenem Sodium | 51 | $17,586 |
| Vancomycin Hcl | 109 | $12,621 |
| MicafunginMicafungin Sodium | 12 | $5,174 |
| Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod | 38 | $4,251 |
| CeftriaxoneCeftriaxone Sodium | 82 | $3,527 |
| Cefepime Hcl | 24 | $3,354 |
| Meropenem | 20 | $3,098 |
| Cefazolin Sodium | 36 | $1,998 |
| Linezolid-D5wLinezolid In Dextrose 5% | 12 | $1,826 |
| Levofloxacin-D5wLevofloxacin In Dextrose 5 % | 29 | $1,256 |
| Fluconazole | 17 | $1,063 |
| Doxycycline Hyclate | 11 | $230 |
| Levofloxacin | 11 | $193 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Mesa
- Adonis JabbourMesa$1K
- Shashikala AmeneniMesa$547
- Thanes VanigPhoenix$258K
- Anita KohliChandler$213K
- Vipul GanatraPhoenix$151K
- Jorge MeraNogales$101K
- Ana MoranPhoenix$35K
- Robert OrensteinPhoenix$26K
- Edward CachayScottsdale$26K
- Aman DalalScottsdale$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.